Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing heterocyclic carbon compound having only o – n – s,...
Reexamination Certificate
2000-10-16
2004-11-30
Marx, Irene (Department: 1651)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing heterocyclic carbon compound having only o, n, s,...
C435S135000, C210S656000, C549S292000
Reexamination Certificate
active
06825015
ABSTRACT:
BACKGROUND OF THE INVENTION
Lovastatin, pravastatin, mevastatin, simvastatin, their derivatives and analogs are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. They are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus.
Purity of the active ingredient is an important factor for the manufacturing of a safe and effective pharmaceutical. The highest possible purity of the product is especially important if the pharmaceutical product should be taken for a longer period as is the case in the treatment or the preventing of a high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity can cause many side effects during the medical treatment.
The processes for the isolation and purification of the antihypercholesterolemic agents disclosed in the earlier patent applications comprise different combinations of extraction, chromatography, lactonization and crystallization methods. The purity of the final product obtained by these procedures is lower than 99.6%. Obtaining the product of higher purity by use of these methods is possible, but the yield of the desired product is then unacceptably low for using those methods in a large industrial scale.
The isolation process disclosed in patent application WO 92/16276 provides the solution for obtaining HMG-CoA reductase inhibitors of purity higher than 99.5%, but the use of highly sophisticated industrial high performance liquid chromatography (HPLC) equipment is required. According to the WO 92/16276 the crude HMG-CoA reductase inhibitor of approximately 85% or higher purity is dissolved in an organic solvent or in a solution of organic solvent and water. The mixture is then buffered to a pH between 2 and 9 and placed on an HPLC column. After the HMG-CoA reductase inhibitor peak of interest is collected, a portion of solvent is removed and then water is added or alternatively two-thirds of the solvent mixture are removed to crystallize the HMG-CoA reductase inhibitor. At the end the purity of the product achieved by this process is really at least 99.5% with yield of approximately 90%.
SUMMARY OF THE INVENTION
The present invention relates to a new industrial process for isolation and purification of HMG-CoA reductase inhibitors of purity higher than 99.6% and preferably higher than 99.7% from a fermentation broth. To achieve this goal an extensive study of the chemical compounds produced during the fermentation using the different species of microorganisms belonging to Aspergillus, Monascus, Nocardia, Mucor, Amnycolatopsis or Penicillium genus, their chemical properties and their behavior in the different solvents at different pH was done. Thus, the aforementioned object was solved by the process of the present invention which comprises the following steps:
clarifying a mycelium broth and concentrating the clarified broth to a lower volume,
acidifying of the concentrate to a pH value in the range of 4.5 to 7.5, followed by extracting the HMG-CoA reductase inhibitor with ethyl acetate,
optionally performing lactonization,
performing crystallization of the HMG-CoA reductase inhibitor from a water-miscible or water-soluble organic solvent, and
performing crystallization of the HMG-CoA reductase inhibitor from an organic solvent having limited miscibility or solubility with water.
REFERENCES:
patent: 4294846 (1981-10-01), Albers-Schonberg et al.
patent: 4319039 (1982-03-01), Albers-Schonberg
patent: 4965200 (1990-10-01), Chen et al.
patent: 0 251 625 (1988-01-01), None
patent: WO 92/16276 (1992-10-01), None
patent: WO 97/06128 (1997-02-01), None
patent: WO 97/20834 (1997-06-01), None
patent: WO 01/03647 (2001-01-01), None
Chan, C., et al. “Inhibitors of Cholesterol Biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a Novel Series of hMG-Coa Reductase Inhibitors,”J. Med. Chem.,1993, vol. 36, pp. 3646-3657.
Procopiou, P., et al. “Inhibitors of Cholesterol Biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates and -heptanoates, a Novel Series of hMG-Coa Reductase Inhibitors,”J. Med. Chem,,1993, vol. 36, pp. 3658-3662.
Milivojevic Dusan
Pflaum Zlatko
Senica David
Bromberg & Sunstein LLP
LEK Pharmaceuticals d.d.
Marx Irene
LandOfFree
Process for the obtaining of HMG-COA reductase inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the obtaining of HMG-COA reductase inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the obtaining of HMG-COA reductase inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3277643